Business Context and Reporting Period
This Form 8-K filing by Spruce Biosciences, Inc. (SPRB) was submitted on April 30, 2024, reporting an event that occurred on April 26, 2024. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary material event is the receipt of a notice from Nasdaq indicating noncompliance with Listing Rule 5450(a)(1). The company's common stock minimum bid price has remained below $1.00 per share for 30 consecutive business days.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The company has a 180-calendar day grace period, ending on October 23, 2024, to regain compliance.
- Remediation Requirement: To cure the deficiency, the stock price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days within the grace period.
- Alternative Path: If compliance is not achieved by the deadline, the company may be eligible for an additional 180-day period if it transfers to the Nasdaq Capital Market, subject to meeting other listing standards (excluding the bid price requirement).
- Risks: Failure to regain compliance could result in the delisting of the company's common stock. Management stated there is no assurance that compliance will be achieved.
- Management Action: The company intends to actively monitor the bid price and consider available options to regain compliance.
Investor Verification Checklist
- Verify the current trading price of SPRB common stock relative to the $1.00 threshold.
- Monitor the company's stock price performance over the next 10 consecutive business days to assess immediate compliance progress.
- Review future filings for any announcements regarding a potential transfer to the Nasdaq Capital Market.
- Check for any reverse stock split proposals or other corporate actions intended to address the low bid price.